Division of Cardiovascular Medicine, Ohio State University, USA.
Cardio-Oncology Program, Division of Cardiovascular Medicine, University of South Florida, 2 Tampa General Circle, Tampa, FL, 33606, USA; Cardio-Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA.
Trends Cardiovasc Med. 2019 Jan;29(1):29-39. doi: 10.1016/j.tcm.2018.06.001. Epub 2018 Jun 8.
There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.
在肿瘤学领域取得了重大进展，由于新型靶向治疗和免疫疗法的出现，生存率得到了提高。尽管取得了这些改善的结果，但人们越来越认识到这些疗法与心脏毒性有关，这些毒性可导致严重的发病率和死亡率。因此，心脏肿瘤学领域在过去几年中得到了显著发展。在这篇综述中，我们讨论了心脏肿瘤学领域的最新进展，并详细讨论了与新型癌症治疗药物相关的心血管并发症，包括酪氨酸激酶抑制剂、蛋白酶体抑制剂、组蛋白去乙酰化酶抑制剂、CDK4/6 抑制剂和免疫疗法。
